文献速递关节外科创伤骨科

围手术期药物优化症状性良性前列腺增生在全关节置换术中具有经济合理的感染预防价值

Perioperative Medical Optimization of Symptomatic Benign Prostatic Hyperplasia Is an Economically Justified Infection Prevention Strategy in Total Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2021-02-27

本研究通过盈亏平衡分析评估了在全关节置换术(TJA)前对症状性良性前列腺增生(BPH)进行围手术期排尿优化的经济性。构建包含坦索罗辛单药、联合非那雄胺及经尿道前列腺电切的三条路径模型。结果显示药物路径在较低绝对风险降低下即可具成本效益,而手术路径仅在计入假体周围感染(PJI)长期社会成本时成立。

要点

  • 路径1(坦索罗辛6周)预防1例TKA感染需治疗113例(ARR=0.883%),THA需140例(ARR=0.714%)。
  • 路径2(联合治疗6个月)预防1例TKA感染需治疗69例(ARR=1.445%),THA需86例(ARR=1.169%)。
  • 路径3(手术)仅在PJI治疗成本为40万美元时具成本效益(NNT=71,ARR=1.406%)。

核心结论

  • 围手术期药物管理症状性BPH是经济合理的PJI预防策略。
  • 手术干预仅在考虑PJI长期社会成本时才有财务依据。

研究设计与样本

  • 基于文献与机构采购记录的成本数据进行盈亏平衡经济模型分析。
  • 构建三条围手术期排尿优化路径:坦索罗辛6周、联合治疗6个月、经尿道前列腺电切。

主要发现

  • 路径1预防1例TKA感染需治疗113例(ARR=0.883%),THA需140例(ARR=0.714%)。
  • 路径2预防1例TKA感染需治疗69例(ARR=1.445%),THA需86例(ARR=1.169%)。
  • 路径3在假设PJI治疗成本为40万美元时成本效益成立(NNT=71,ARR=1.406%)。
  • 路径1和2的成本效益在排尿优化成本、感染率和PJI成本变化下保持稳定。

关键数值与推荐

  • 路径1成本效益阈值:TKA的ARR=0.883%(NNT=113),THA的ARR=0.714%(NNT=140)。
  • 路径2成本效益阈值:TKA的ARR=1.445%(NNT=69),THA的ARR=1.169%(NNT=86)。
  • 路径3成本效益阈值:假设PJI治疗成本40万美元时NNT=71,ARR=1.406%。

临床怎么用

  • 对拟行TJA的症状性BPH患者,可优先考虑围手术期药物优化以降低PJI风险。
  • 药物路径(坦索罗辛单药或联合非那雄胺)在经济上较手术路径更易成立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abnormal voiding dynamics may be a modifiable risk factor for prosthetic joint infection (PJI) after total joint arthroplasty (TJA), but the cost-effectiveness of their optimization in the perioperative setting is unknown. Using a break-even analysis, we calculated the economic viability of perioperative voiding optimization for infection prevention after TJA in patients with symptomatic benign prostatic hyperplasia (BPH). METHODS: A perioperative voiding optimization algorithm was created to represent a common approach to treating symptomatic BPH before TJA. Treatment is initiated with a 6-week trial of tamsulosin (pathway 1), followed by 6 months of combination tamsulosin/finasteride therapy (pathway 2) if symptoms persist. Patients with unremitting symptoms after medical management undergo surgical correction with transurethral resection of the prostate (pathway 3). Costs associated with each pathway were derived from the literature and institutional purchasing records. A break-even economic model was constructed to calculate the absolute risk reduction (ARR) in the infection rate and number needed to treat necessary for cost-effectiveness. RESULTS: Pathway 1 was cost-effective if it prevented 1 infection of 113 (ARR = 0.883%) TKAs or 140 (ARR = 0.714%) THAs. Pathway 2 was cost-effective if it obviated infection in 1 of 69 TKAs (ARR = 1.445%) or 86 THAs (ARR = 1.169%). Pathway 3 was only deemed cost-effective assuming a cost of $400,000 to treat a PJI (number needed to treat = 71, ARR = 1.406%). Cost-effectiveness for pathways 1 and 2 was maintained with varying voiding optimization costs, infection rates, and PJI costs. CONCLUSION: Perioperative medical management of symptomatic BPH is an economically justified PJI prevention strategy, whereas surgical interventions appear to be financially substantiated only when considering the long-term societal costs of a PJI.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Moverman MA, Bruha MJ, Pagani NR, et al. Perioperative Medical Optimization of Symptomatic Benign Prostatic Hyperplasia Is an Economically Justified Infection Prevention Strategy in Total Joint Arthroplasty. J Arthroplasty. 2021. PMID: 33775467. doi:10.1016/j.arth.2021.02.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。